Form 4: BIOVIE Director Acquires 421,100 Stock Options

BIOVIE Inc. Director Michael Edward Sherman reported the acquisition of 421,100 stock options with an exercise price of $1.31, vesting over several years.

Summary

• Michael Edward Sherman, a Director of BIOVIE INC. (BIVI), reported the acquisition of derivative securities (stock options).
• The transaction date for these acquisitions was January 5, 2026.
• Sherman acquired two grants of stock options totaling 421,100 options.
• The first grant consists of 80,000 stock options with an exercise price of $1.31, expiring on January 5, 2031. These options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026, or the date of the registrant's 2026 annual shareholders' meeting.
• The second grant consists of 341,100 stock options with an exercise price of $1.31, expiring on January 5, 2031. 75% of these options vested on January 5, 2026, with the remaining portion vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.
• Following these transactions, Sherman beneficially owns a total of 421,100 direct stock options.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director, particularly with a vesting schedule, generally indicates a commitment to the company's long-term success and an alignment of interests with shareholders.

Positives

• Director Michael Edward Sherman acquired 421,100 stock options, indicating a potential alignment of interests with shareholders.
• The options have an exercise price of $1.31, suggesting a belief in the company's future stock price appreciation above this level.

Risks

• The value of the stock options is dependent on the future market price of BIOVIE INC. common stock exceeding the exercise price of $1.31.
• The vesting schedules mean that a significant portion of the options are not immediately exercisable, tying the director's compensation to future performance.

Future Outlook

The vesting schedules for the acquired stock options extend through January 2029, indicating a long-term incentive structure for Director Michael Edward Sherman and aligning his interests with the company's future performance. The options themselves expire in 2031.

Industry Context

Insider transactions, such as the grant of stock options to a director, are a common form of executive and director compensation in publicly traded companies, particularly in the biotechnology sector (implied by BIOVIE INC.). These grants are designed to align the interests of company leadership with those of shareholders by incentivizing long-term stock price appreciation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice across industries, including biotechnology. The specific number of options (421,100) and the exercise price ($1.31) would typically be evaluated against peer company compensation packages and the company's market capitalization and stage of development. Without specific peer data, a direct comparison is not feasible from this filing alone.

Related Party Transactions

• The acquisition of stock options by Director Michael Edward Sherman from BIOVIE INC. constitutes a related party transaction, as it involves a transaction between the company and one of its directors.

Stakeholder Impact

• Shareholders: May view the option grants as a positive sign of management's commitment and belief in future stock appreciation, potentially aligning director incentives with shareholder value creation.

Next Steps

• Future vesting dates for the stock options on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026, or the 2026 annual shareholders' meeting for the first grant.
• Future vesting dates for the second grant on January 5, 2027, January 5, 2028, and January 5, 2029.
• Potential exercise of options by Michael Edward Sherman on or after their respective vesting dates and before the expiration date of January 5, 2031.

Key Dates

Keywords

BIOVIE INC., BIVI, Michael Edward Sherman, Director, Stock Options, Insider Transaction, Form 4, SEC Filing, Beneficial Ownership, Equity Compensation, Vesting